Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.50 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.43 |
| ▸ | CHRNA5 | P30532 | 3/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2275501 | 1.00 | SCD (0.50) | SCDHCRTR2NPC1RAB9AMAPT | |
| SCHEMBL27789101 | 0.87 | SCD (0.57) | SCDHCRTR2NPC1RAB9AMAPT | |
| SCHEMBL27789100 | 0.87 | SCD (0.57) | SCDHCRTR2NPC1RAB9AMAPT | |
| SCHEMBL15848655 | 0.85 | HCRTR2 (0.60) | HCRTR2GRM5 | |
| SCHEMBL15848653 | 0.85 | HCRTR2 (0.60) | HCRTR2GRM5 | |
| SCHEMBL3852300 | 0.81 | HCRTR2 (0.49) | SCDHCRTR2MAPTUSP30GPR119 | |
| SCHEMBL23992271 | 0.80 | ALDH1A1 (0.56) | MAPTCHRNB2CHRNA5CHRNA4LMNA | |
| SCHEMBL30148091 | 0.80 | ALDH1A1 (0.56) | MAPTCHRNB2CHRNA5CHRNA4LMNA | |
| SCHEMBL24114777 | 0.80 | ALDH1A1 (0.56) | MAPTCHRNB2CHRNA5CHRNA4LMNA | |
| SCHEMBL3667865 | 0.79 | USP30 (0.51) | MAPTUSP30LMNAKMT2AUCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBVIE INC (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2974727-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | Abbvie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9186407-B2 | Pharmaceutical compositions and their methods of use | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2226074-B1 | Pharmaceutical compositions and their methods of use | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-9040568-B2 | Pharmaceutical compositions for the treatment of pain | ABBVIE INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-8486979-B2 | Analgesics; central nervous system disorders; attentiondeficit disorders;cognition activators; bipolar disorders; Alzheimer's disease; Down's syndrome; brain disorders | ABBVIE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2101763-B1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LAB (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20110190314-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010138600-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305086-A1 | Pharmaceutical Compositions for the Treatment of Pain | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2226074-A2 | Pharmaceutical compositions and their methods of use | Abbott Laboratories (US) | 2010-09-08 | — | — | EP | disclosed |
| EP-2101763-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20080269236-A1 | Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008073942-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190314-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | CHRNA4, CHRNB4, CHRNA5 | SCD 2565/4885HCRTR2 322/4885NPC1 1677/4885 |
| US-20100305086-A1 | Pharmaceutical Compositions for the Treatment of Pain | CHRNA1, CHRNG, CHRNA4 | SCD 2950/4885HCRTR2 334/4885NPC1 2912/4885 |
| US-20080269236-A1 | Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof | OXA1L, CYP11B2, CYP1B1 | SCD 2873/4885HCRTR2 285/4885NPC1 1201/4885 |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | CHRNA4, CHRNB4, CHRNA5 | SCD 2565/4885HCRTR2 322/4885NPC1 1677/4885 |
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | CHRNA4, CHRNB4, CHRNA5 | SCD 2565/4885HCRTR2 322/4885NPC1 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.